Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a shampoo stop hair loss? new study says maybe

NCT ID NCT07433933

Symptom relief Sponsor: Lacer S.A. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a special shampoo for people with hair loss from telogen effluvium or early male/female pattern baldness. 40 adults used the shampoo for 3 months. The goal was to see if it improved hair length and thickness. The study is now complete.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

40 people

The number who actually took part.

Started

May 2025

Finished

Oct 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Clinic database

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Sex: Both (50% women; 50% men). * Age: 18-65 years. * Subjects with hair loss due to telogen effluvium or mild or incipient androgenic alopecia, in an 80/20 ratio. * Degree of androgenic alopecia: Ludwig scale score I-II for women and Hamilton-Norwood scale score III-II for men. * Telogen effluvium: Combing test. * Subjects with all hair types (oily, combination, sensitive, etc.). * Subjects with all scalp types (normal, sensitive, etc.). * Agree to participate voluntarily in the study and provide written informed consent. * Adequate level of understanding of the clinical study. * Good health (physical and mental). * Availability to attend visits to the research centres. * No application of any product to the experimental area on the first day of the trial. Exclusion Criteria: * Individuals under 18 years of age. * Pregnant or breastfeeding women. * Injuries or infection in the test area. * History of allergies to cosmetic products. * Known allergies to product components. * Sensitivity to any product component. * Patients who have undergone recent surgery or treatments in the study area. * Cancer patients. * Volunteers currently taking antibiotics, antihistamines, corticosteroids, beta-blockers, retinoids, azelaic acid, or acne therapies, or whose treatment ended within 15 days prior to the start of the study. Participation in another clinical study. * Use of or having used cosmetic products and/or oral or topical treatments for hair loss for at least 6 months. * Hair cutting or dyeing during the study. * Health problems, to be assessed by the specialist, that may compromise adherence to the study protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Androgenetic alopecia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

alopecia androgenetic alopecia telogen effluvium

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Androgenetic alopecia Telogen effluvium

Contacts and locations

Locations

  • Centro Médico Complutense Grupo Virtus

    Alcalá de Henares, Madrid, 28805, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.